Key facts
- Notable investors include National Institutes of Health, National Cancer Institute, Yuvaan Tiwari Foundation.
- Targepeutics has filed 1 Form D with the SEC, most recently Jun 2025 ($200K sold to 1 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Targepeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Targepeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Targepeutics
Operator of a biopharmaceutical company intended to develop molecularly targeted therapeutics to fight cancer and other diseases. The company's services include drug discovery, research and development, and clinical design, enabling medical industry players to treat and destroy cancer cells with minimal normal cell damage.
- Sector
- Healthcare
- HQ
- Hummelstown, PA, United States
- Founded
- 1997
- Employees
- 3
- Website
- targepeutics.com/
- Ownership
- Privately Held (backing)
Targepeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Targepeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Targepeutics in its N-PORT filings yet. We sweep new filings monthly.